LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Topical Erythropoietin Accelerates Wound Closure in Patients with Diabetic Foot Ulcers: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial.

    Hamed, Saher / Ullmann, Yehuda / Belokopytov, Mark / Shoufani, Aziz / Kabha, Hoda / Masri, Suher / Feldbrin, Zeev / Kogan, Leonid / Kruchevsky, Danny / Najjar, Roger / Liu, Paul Y / Kerihuel, Jean-Charles / Akita, Sadanori / Teot, Luc

    Rejuvenation research

    2021  Volume 24, Issue 4, Page(s) 251–261

    Abstract: The diabetic foot ulcer (DFU) is a major disabling complication of diabetes mellitus. Growing evidence suggests that topical erythropoietin (EPO) can promote wound healing. The aim of this study is to clinically assess the efficacy of a proprietary ... ...

    Abstract The diabetic foot ulcer (DFU) is a major disabling complication of diabetes mellitus. Growing evidence suggests that topical erythropoietin (EPO) can promote wound healing. The aim of this study is to clinically assess the efficacy of a proprietary topical EPO-containing hydrogel for treating DFUs. We conducted a randomized, controlled trial in 20 patients with DFUs. After a 14-day screening period, the DFUs of 20 eligible participants who fulfilled the inclusion criteria were randomly assigned (1:1) to either a 12-week of daily treatment with topical EPO and standard-of-care (SOC) or SOC treatment alone. The DFUs were assessed weekly until week 12. The primary outcome was 75% ulcer closure or higher. After 12 weeks of treatment, 75% ulcer closure was achieved in 6 of the 10 patients whose DFUs were treated with topical EPO and in one of the 8 patients whose DFUs were treated with SOC alone. The mean area of the DFUs that were treated with topical EPO and SOC was significantly smaller than those treated with SOC alone (1.2 ± 1.4 cm
    MeSH term(s) Diabetes Mellitus ; Diabetic Foot/drug therapy ; Erythropoietin/therapeutic use ; Humans ; Prospective Studies ; Single-Blind Method ; Treatment Outcome ; Wound Healing
    Chemical Substances Erythropoietin (11096-26-7)
    Language English
    Publishing date 2021-04-01
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 2150779-X
    ISSN 1557-8577 ; 1549-1684
    ISSN (online) 1557-8577
    ISSN 1549-1684
    DOI 10.1089/rej.2020.2397
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Topical Erythropoietin Treatment Accelerates the Healing of Cutaneous Burn Wounds in Diabetic Pigs Through an Aquaporin-3-Dependent Mechanism.

    Hamed, Saher / Ullmann, Yehuda / Egozi, Dana / Keren, Aviad / Daod, Essam / Anis, Omer / Kabha, Hoda / Belokopytov, Mark / Ashkar, Manal / Shofti, Rona / Zaretsky, Asaph / Schlesinger, Michal / Teot, Luc / Liu, Paul Y

    Diabetes

    2017  Volume 66, Issue 8, Page(s) 2254–2265

    Abstract: We have previously reported that the topical application of erythropoietin (EPO) to cutaneous wounds in rats and mice with experimentally induced diabetes accelerates their healing by stimulating angiogenesis, reepithelialization, and collagen deposition, ...

    Abstract We have previously reported that the topical application of erythropoietin (EPO) to cutaneous wounds in rats and mice with experimentally induced diabetes accelerates their healing by stimulating angiogenesis, reepithelialization, and collagen deposition, and by suppressing the inflammatory response and apoptosis. Aquaporins (AQPs) are integral membrane proteins whose function is to regulate intracellular fluid hemostasis by enabling the transport of water and glycerol. AQP3 is the AQP that is expressed in the skin where it facilitates cell migration and proliferation and re-epithelialization during wound healing. In this report, we provide the results of an investigation that examined the contribution of AQP3 to the mechanism of EPO action on the healing of burn wounds in the skin of pigs with experimentally induced type 1 diabetes. We found that topical EPO treatment of the burns accelerated their healing through an AQP3-dependent mechanism that activates angiogenesis, triggers collagen and hyaluronic acid synthesis and the formation of the extracellular matrix (ECM), and stimulates reepithelialization by keratinocytes. We also found that incorporating fibronectin, a crucial constituent of the ECM, into the topical EPO-containing gel, can potentiate the accelerating action of EPO on the healing of the burn injury.
    MeSH term(s) Administration, Topical ; Angiogenesis Inducing Agents/administration & dosage ; Animals ; Aquaporin 3/metabolism ; Burns/drug therapy ; Burns/genetics ; Collagen/genetics ; Diabetes Mellitus, Experimental/genetics ; Diabetes Mellitus, Type 1/genetics ; Erythropoietin/administration & dosage ; Extracellular Matrix/genetics ; Fibronectins/administration & dosage ; Hyaluronic Acid/biosynthesis ; Keratinocytes/metabolism ; Neovascularization, Physiologic ; Re-Epithelialization/genetics ; Skin/metabolism ; Swine ; Wound Healing/drug effects ; Wound Healing/genetics
    Chemical Substances Angiogenesis Inducing Agents ; Fibronectins ; Erythropoietin (11096-26-7) ; Aquaporin 3 (158801-98-0) ; Hyaluronic Acid (9004-61-9) ; Collagen (9007-34-5)
    Language English
    Publishing date 2017-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80085-5
    ISSN 1939-327X ; 0012-1797
    ISSN (online) 1939-327X
    ISSN 0012-1797
    DOI 10.2337/db16-1205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.

    Bar-Am, Orit / Amit, Tamar / Kupershmidt, Lana / Aluf, Yuval / Mechlovich, Danit / Kabha, Hoda / Danovitch, Lena / Zurawski, Vincent R / Youdim, Moussa B H / Weinreb, Orly

    Neurobiology of aging

    2015  Volume 36, Issue 3, Page(s) 1529–1542

    Abstract: Recently, we have designed and synthesized a novel multipotent, brain-permeable iron-chelating drug, VAR10303 (VAR), possessing both propargyl and monoamine oxidase (MAO) inhibitory moieties. The present study was undertaken to determine the multiple ... ...

    Abstract Recently, we have designed and synthesized a novel multipotent, brain-permeable iron-chelating drug, VAR10303 (VAR), possessing both propargyl and monoamine oxidase (MAO) inhibitory moieties. The present study was undertaken to determine the multiple pharmacological activities of VAR in neurodegenerative preclinical models. We demonstrate that VAR affords iron chelating/iron-induced lipid-peroxidation inhibitory potency and brain selective MAO-A and MAO-B inhibitory effects, with only limited tyramine-cardiovascular potentiation of blood pressure. The results show that in 6-hydroxydopamine rat (neuroprotection) and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse (neurorescue) Parkinson's disease models, VAR significantly attenuated the loss of striatal dopamine levels, markedly reduced dopamine turnover, and increased tyrosine-hydroxylase levels. Furthermore, chronic systemic treatment of aged rats with VAR improved cognitive behavior deficits and enhanced the expression levels of neurotrophic factors (e.g., brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, and nerve growth factor), Bcl-2 family members and synaptic plasticity in the hippocampus. Our study indicates that the multitarget compound VAR exerted neuroprotective and neurorestorative effects in animal models of Parkinson's disease and aging, further suggesting that a drug that can regulate multiple brain targets could be an ideal treatment-strategy for age-associated neurodegenerative disorders.
    MeSH term(s) Aging ; Animals ; Cognition ; Disease Models, Animal ; Dopamine/metabolism ; Hydroxyquinolines/pharmacology ; Hydroxyquinolines/therapeutic use ; Iron Chelating Agents/pharmacology ; Iron Chelating Agents/therapeutic use ; Male ; Mice, Inbred C57BL ; Molecular Targeted Therapy ; Monoamine Oxidase ; Monoamine Oxidase Inhibitors/pharmacology ; Monoamine Oxidase Inhibitors/therapeutic use ; Nerve Growth Factors/metabolism ; Neuronal Plasticity/drug effects ; Neuroprotective Agents ; Parkinson Disease/drug therapy ; Parkinson Disease/genetics ; Parkinson Disease/metabolism ; Parkinson Disease/psychology ; Rats, Sprague-Dawley
    Chemical Substances 5-(2-(methylprop-2-ynylamino)ethyl)quinolin-8-ol ; Hydroxyquinolines ; Iron Chelating Agents ; Monoamine Oxidase Inhibitors ; Nerve Growth Factors ; Neuroprotective Agents ; Monoamine Oxidase (EC 1.4.3.4) ; Dopamine (VTD58H1Z2X)
    Language English
    Publishing date 2015-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604505-4
    ISSN 1558-1497 ; 0197-4580
    ISSN (online) 1558-1497
    ISSN 0197-4580
    DOI 10.1016/j.neurobiolaging.2014.10.026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top